Skip to content
  • Facebook
  • Twitter
This translation is automatically provided by Google; please refer to the original English version for appropriate wording.
Take on Typhoid

Take on Typhoid

  • Home
  • Why Typhoid?
    • Typhoid & Related Salmonelloses
    • Global Research
    • Links & Resources
  • The Issues
    • Vaccines
    • WASH
    • Drug-Resistant Typhoid
    • Treatment
    • Diagnostics
    • Typhoid intestinal perforation
    • Related Issues
  • Resources & Tools
    • Talk About Typhoid
    • Global Policy
    • Country Tools
    • Infographics
    • Fact Sheets
    • TCV Cost-effectiveness
    • Share on Social
  • Blog & News
    • Blog
    • News
    • Publications
    • Newsletter
  • International Conference
    • Past Conferences
    • Conference Travel
  • About Us
    • About the Coalition against Typhoid
    • About the Typhoid Vaccine Acceleration Consortium

New trial investigates typhoid conjugate vaccine in Africa

Posted on February 28, 2018 by admin
  • The Typhoid Vaccine Acceleration Consortium, or TyVAC, recently launched a trial assessing the effectiveness and cost-effectiveness of the new typhoid conjugate vaccine, Typbar TCV®, among children in Malawi

Post navigation

Malawi is first African nation using new WHO approved typhoid vaccine
Increased Diagnoses of Typhoid Fever, Shigellosis Linked to SE Asia Visits

Newsletter Signup

Recent Posts

  • TCV: An early defense against typhoid in extreme weather conditions

  • Can better diagnostics improve typhoid prevention and treatment?

  • Réponse immunitaire robuste à la dose de rappel du vaccin antityphoïdique chez les enfants âgés de cinq ans au Malawi

  • Robust immune response to typhoid booster vaccination at five years in Malawi

  • The journey of a vaccine: from production to protection

cat
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Coalition against Typhoid
2175 K Street, NW, Suite 400
Washington, DC 20037
© 2018. Coalition Against Typhoid. All Rights Reserved.
  • Contact Us
  • Privacy Policy
  • Facebook
  • Twitter
Top